A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer
Purpose Breast cancer is a group of diseases with different intrinsic molecular subtypes. However, anatomic staging alone is insufficient to determine prognosis. The present study analyzed the prognostic value of the American Joint Committee for Cancer (AJCC) 8th edition cancer staging system. Metho...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2018-06, Vol.169 (2), p.257-266 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 266 |
|---|---|
| container_issue | 2 |
| container_start_page | 257 |
| container_title | Breast cancer research and treatment |
| container_volume | 169 |
| creator | Lee, Sae Byul Sohn, Guiyun Kim, Jisun Chung, Il Yong Lee, Jong Won Kim, Hee Jeong Ko, Beom Seok Son, Byung Ho Ahn, Sei-Hyun |
| description | Purpose
Breast cancer is a group of diseases with different intrinsic molecular subtypes. However, anatomic staging alone is insufficient to determine prognosis. The present study analyzed the prognostic value of the American Joint Committee for Cancer (AJCC) 8th edition cancer staging system.
Methods
This retrospective, single-center study included breast cancer cases diagnosed from January 1999 to December 2008. We restaged patients based on the 8th edition AJCC cancer staging system and analyzed the prognostic value of the anatomic and prognostic staged groups. Follow-up data including disease-free survival (DFS), overall survival (OS), and clinic-pathological data were collected to analyze the differences between the two staging subgroups.
Results
The study enrolled 7458 breast cancer patients with a 98.7-month median follow-up. Both the 5-year DFS and OS were significantly different between the anatomic and prognostic staged groups. The 5-year OS according to disease subtype was as follows: hormone receptor-positive/human epidermal growth factor receptor 2-negative [HR(+)/HER2(−)], 90.9%; HR(+)/HER2(+), 84.7%; HR(−)/HER2(+), 81.1%; and HR(−)/HER2(−), 80.9%. According to the anatomic stage, the 5-year OS of patients with stage III HR(+)/HER2(−) disease was superior to that of patients with stage II HR(−)/HER2(−) disease (88.3 vs. 86.5%). Per the prognostic stage, both the 5-year DFS and OS rates of patients with stage II HR(−)/HER2(−) disease were higher than those of patients with stage III HR(+)/HER2(−) disease (90.1 and 94.3% vs. 79.1 and 88.9%).
Conclusions
The prognostic staging system is a refined version of the anatomic staging system and encourages a more personalized approach to breast cancer treatment. |
| doi_str_mv | 10.1007/s10549-018-4682-5 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5945740</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A538168427</galeid><sourcerecordid>A538168427</sourcerecordid><originalsourceid>FETCH-LOGICAL-c568t-93afa3860ba25053376da93532640a7c9e6c747dcca17d0fca944c67a63e116f3</originalsourceid><addsrcrecordid>eNp1kt-K3CAUxkNp6c5u-wC9KUKh7E22GqPGm8Iw9C8LvWmvxTEnGZdEp2oG5in2lWtmttuZ0uKF4Pc7n57jVxSvCL4hGIt3kWBWyxKTpqx5U5XsSbEgTNBSVEQ8LRaYcFHyBvOL4jLGO4yxFFg-Ly4qSZsmq4vifokCpODjFkyyO0Db4HvnY7IGwU4Pk07WO6SdHvbRRjRF63qUNoCatEHQ2oPsu8PRcoRgjXboq7cuoZUfR5sSAMrISjsDAcWk-9kh7mOCEXU-oHUAHRMyB-BF8azTQ4SXD_tV8ePjh--rz-Xtt09fVsvb0jDepFJS3WnacLzWFcOMUsFbLSmjFa-xFkYCN6IWrTGaiBZ3Rsu6NlxoToEQ3tGr4v3RdzutR2gNuBT0oLbBjjrslddWnSvOblTvd4rJmokaZ4PrB4Pgf04QkxptNDAM2oGfoiJSUtrUkrGMvvkLvfNTyBM9Uhznd5M_VK8HUNZ1Pt9rZlO1ZLQhvKkrkambf1B5tTBa4x10Np-fFbw9KdiAHtIm-mGa_y2eg-QImpyGGKB7HAbBao6bOsZN5bipOW5q7uz16RQfK37nKwPVEYhZcj2Ek9b_6_oLDBfgtw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1993603531</pqid></control><display><type>article</type><title>A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Lee, Sae Byul ; Sohn, Guiyun ; Kim, Jisun ; Chung, Il Yong ; Lee, Jong Won ; Kim, Hee Jeong ; Ko, Beom Seok ; Son, Byung Ho ; Ahn, Sei-Hyun</creator><creatorcontrib>Lee, Sae Byul ; Sohn, Guiyun ; Kim, Jisun ; Chung, Il Yong ; Lee, Jong Won ; Kim, Hee Jeong ; Ko, Beom Seok ; Son, Byung Ho ; Ahn, Sei-Hyun</creatorcontrib><description>Purpose
Breast cancer is a group of diseases with different intrinsic molecular subtypes. However, anatomic staging alone is insufficient to determine prognosis. The present study analyzed the prognostic value of the American Joint Committee for Cancer (AJCC) 8th edition cancer staging system.
Methods
This retrospective, single-center study included breast cancer cases diagnosed from January 1999 to December 2008. We restaged patients based on the 8th edition AJCC cancer staging system and analyzed the prognostic value of the anatomic and prognostic staged groups. Follow-up data including disease-free survival (DFS), overall survival (OS), and clinic-pathological data were collected to analyze the differences between the two staging subgroups.
Results
The study enrolled 7458 breast cancer patients with a 98.7-month median follow-up. Both the 5-year DFS and OS were significantly different between the anatomic and prognostic staged groups. The 5-year OS according to disease subtype was as follows: hormone receptor-positive/human epidermal growth factor receptor 2-negative [HR(+)/HER2(−)], 90.9%; HR(+)/HER2(+), 84.7%; HR(−)/HER2(+), 81.1%; and HR(−)/HER2(−), 80.9%. According to the anatomic stage, the 5-year OS of patients with stage III HR(+)/HER2(−) disease was superior to that of patients with stage II HR(−)/HER2(−) disease (88.3 vs. 86.5%). Per the prognostic stage, both the 5-year DFS and OS rates of patients with stage II HR(−)/HER2(−) disease were higher than those of patients with stage III HR(+)/HER2(−) disease (90.1 and 94.3% vs. 79.1 and 88.9%).
Conclusions
The prognostic staging system is a refined version of the anatomic staging system and encourages a more personalized approach to breast cancer treatment.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-018-4682-5</identifier><identifier>PMID: 29388016</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adult ; Aged ; Breast cancer ; Breast Neoplasms - diagnosis ; Breast Neoplasms - epidemiology ; Breast Neoplasms - pathology ; Cancer research ; Cancer staging ; Data processing ; Development and progression ; Disease ; Disease-Free Survival ; Epidermal growth factor ; ErbB-2 protein ; Female ; Humans ; Kaplan-Meier Estimate ; Mastectomy ; Medical prognosis ; Medical research ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Staging - trends ; Oncology ; Precision Medicine - trends ; Preclinical Study ; Prognosis ; Survival ; United States</subject><ispartof>Breast cancer research and treatment, 2018-06, Vol.169 (2), p.257-266</ispartof><rights>The Author(s) 2018</rights><rights>COPYRIGHT 2018 Springer</rights><rights>Breast Cancer Research and Treatment is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c568t-93afa3860ba25053376da93532640a7c9e6c747dcca17d0fca944c67a63e116f3</citedby><cites>FETCH-LOGICAL-c568t-93afa3860ba25053376da93532640a7c9e6c747dcca17d0fca944c67a63e116f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-018-4682-5$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-018-4682-5$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29388016$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Sae Byul</creatorcontrib><creatorcontrib>Sohn, Guiyun</creatorcontrib><creatorcontrib>Kim, Jisun</creatorcontrib><creatorcontrib>Chung, Il Yong</creatorcontrib><creatorcontrib>Lee, Jong Won</creatorcontrib><creatorcontrib>Kim, Hee Jeong</creatorcontrib><creatorcontrib>Ko, Beom Seok</creatorcontrib><creatorcontrib>Son, Byung Ho</creatorcontrib><creatorcontrib>Ahn, Sei-Hyun</creatorcontrib><title>A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Purpose
Breast cancer is a group of diseases with different intrinsic molecular subtypes. However, anatomic staging alone is insufficient to determine prognosis. The present study analyzed the prognostic value of the American Joint Committee for Cancer (AJCC) 8th edition cancer staging system.
Methods
This retrospective, single-center study included breast cancer cases diagnosed from January 1999 to December 2008. We restaged patients based on the 8th edition AJCC cancer staging system and analyzed the prognostic value of the anatomic and prognostic staged groups. Follow-up data including disease-free survival (DFS), overall survival (OS), and clinic-pathological data were collected to analyze the differences between the two staging subgroups.
Results
The study enrolled 7458 breast cancer patients with a 98.7-month median follow-up. Both the 5-year DFS and OS were significantly different between the anatomic and prognostic staged groups. The 5-year OS according to disease subtype was as follows: hormone receptor-positive/human epidermal growth factor receptor 2-negative [HR(+)/HER2(−)], 90.9%; HR(+)/HER2(+), 84.7%; HR(−)/HER2(+), 81.1%; and HR(−)/HER2(−), 80.9%. According to the anatomic stage, the 5-year OS of patients with stage III HR(+)/HER2(−) disease was superior to that of patients with stage II HR(−)/HER2(−) disease (88.3 vs. 86.5%). Per the prognostic stage, both the 5-year DFS and OS rates of patients with stage II HR(−)/HER2(−) disease were higher than those of patients with stage III HR(+)/HER2(−) disease (90.1 and 94.3% vs. 79.1 and 88.9%).
Conclusions
The prognostic staging system is a refined version of the anatomic staging system and encourages a more personalized approach to breast cancer treatment.</description><subject>Adult</subject><subject>Aged</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer research</subject><subject>Cancer staging</subject><subject>Data processing</subject><subject>Development and progression</subject><subject>Disease</subject><subject>Disease-Free Survival</subject><subject>Epidermal growth factor</subject><subject>ErbB-2 protein</subject><subject>Female</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Mastectomy</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Staging - trends</subject><subject>Oncology</subject><subject>Precision Medicine - trends</subject><subject>Preclinical Study</subject><subject>Prognosis</subject><subject>Survival</subject><subject>United States</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kt-K3CAUxkNp6c5u-wC9KUKh7E22GqPGm8Iw9C8LvWmvxTEnGZdEp2oG5in2lWtmttuZ0uKF4Pc7n57jVxSvCL4hGIt3kWBWyxKTpqx5U5XsSbEgTNBSVEQ8LRaYcFHyBvOL4jLGO4yxFFg-Ly4qSZsmq4vifokCpODjFkyyO0Db4HvnY7IGwU4Pk07WO6SdHvbRRjRF63qUNoCatEHQ2oPsu8PRcoRgjXboq7cuoZUfR5sSAMrISjsDAcWk-9kh7mOCEXU-oHUAHRMyB-BF8azTQ4SXD_tV8ePjh--rz-Xtt09fVsvb0jDepFJS3WnacLzWFcOMUsFbLSmjFa-xFkYCN6IWrTGaiBZ3Rsu6NlxoToEQ3tGr4v3RdzutR2gNuBT0oLbBjjrslddWnSvOblTvd4rJmokaZ4PrB4Pgf04QkxptNDAM2oGfoiJSUtrUkrGMvvkLvfNTyBM9Uhznd5M_VK8HUNZ1Pt9rZlO1ZLQhvKkrkambf1B5tTBa4x10Np-fFbw9KdiAHtIm-mGa_y2eg-QImpyGGKB7HAbBao6bOsZN5bipOW5q7uz16RQfK37nKwPVEYhZcj2Ek9b_6_oLDBfgtw</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>Lee, Sae Byul</creator><creator>Sohn, Guiyun</creator><creator>Kim, Jisun</creator><creator>Chung, Il Yong</creator><creator>Lee, Jong Won</creator><creator>Kim, Hee Jeong</creator><creator>Ko, Beom Seok</creator><creator>Son, Byung Ho</creator><creator>Ahn, Sei-Hyun</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180601</creationdate><title>A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer</title><author>Lee, Sae Byul ; Sohn, Guiyun ; Kim, Jisun ; Chung, Il Yong ; Lee, Jong Won ; Kim, Hee Jeong ; Ko, Beom Seok ; Son, Byung Ho ; Ahn, Sei-Hyun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c568t-93afa3860ba25053376da93532640a7c9e6c747dcca17d0fca944c67a63e116f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer research</topic><topic>Cancer staging</topic><topic>Data processing</topic><topic>Development and progression</topic><topic>Disease</topic><topic>Disease-Free Survival</topic><topic>Epidermal growth factor</topic><topic>ErbB-2 protein</topic><topic>Female</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Mastectomy</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Staging - trends</topic><topic>Oncology</topic><topic>Precision Medicine - trends</topic><topic>Preclinical Study</topic><topic>Prognosis</topic><topic>Survival</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Sae Byul</creatorcontrib><creatorcontrib>Sohn, Guiyun</creatorcontrib><creatorcontrib>Kim, Jisun</creatorcontrib><creatorcontrib>Chung, Il Yong</creatorcontrib><creatorcontrib>Lee, Jong Won</creatorcontrib><creatorcontrib>Kim, Hee Jeong</creatorcontrib><creatorcontrib>Ko, Beom Seok</creatorcontrib><creatorcontrib>Son, Byung Ho</creatorcontrib><creatorcontrib>Ahn, Sei-Hyun</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Sae Byul</au><au>Sohn, Guiyun</au><au>Kim, Jisun</au><au>Chung, Il Yong</au><au>Lee, Jong Won</au><au>Kim, Hee Jeong</au><au>Ko, Beom Seok</au><au>Son, Byung Ho</au><au>Ahn, Sei-Hyun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2018-06-01</date><risdate>2018</risdate><volume>169</volume><issue>2</issue><spage>257</spage><epage>266</epage><pages>257-266</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><abstract>Purpose
Breast cancer is a group of diseases with different intrinsic molecular subtypes. However, anatomic staging alone is insufficient to determine prognosis. The present study analyzed the prognostic value of the American Joint Committee for Cancer (AJCC) 8th edition cancer staging system.
Methods
This retrospective, single-center study included breast cancer cases diagnosed from January 1999 to December 2008. We restaged patients based on the 8th edition AJCC cancer staging system and analyzed the prognostic value of the anatomic and prognostic staged groups. Follow-up data including disease-free survival (DFS), overall survival (OS), and clinic-pathological data were collected to analyze the differences between the two staging subgroups.
Results
The study enrolled 7458 breast cancer patients with a 98.7-month median follow-up. Both the 5-year DFS and OS were significantly different between the anatomic and prognostic staged groups. The 5-year OS according to disease subtype was as follows: hormone receptor-positive/human epidermal growth factor receptor 2-negative [HR(+)/HER2(−)], 90.9%; HR(+)/HER2(+), 84.7%; HR(−)/HER2(+), 81.1%; and HR(−)/HER2(−), 80.9%. According to the anatomic stage, the 5-year OS of patients with stage III HR(+)/HER2(−) disease was superior to that of patients with stage II HR(−)/HER2(−) disease (88.3 vs. 86.5%). Per the prognostic stage, both the 5-year DFS and OS rates of patients with stage II HR(−)/HER2(−) disease were higher than those of patients with stage III HR(+)/HER2(−) disease (90.1 and 94.3% vs. 79.1 and 88.9%).
Conclusions
The prognostic staging system is a refined version of the anatomic staging system and encourages a more personalized approach to breast cancer treatment.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>29388016</pmid><doi>10.1007/s10549-018-4682-5</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2018-06, Vol.169 (2), p.257-266 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5945740 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Aged Breast cancer Breast Neoplasms - diagnosis Breast Neoplasms - epidemiology Breast Neoplasms - pathology Cancer research Cancer staging Data processing Development and progression Disease Disease-Free Survival Epidermal growth factor ErbB-2 protein Female Humans Kaplan-Meier Estimate Mastectomy Medical prognosis Medical research Medicine Medicine & Public Health Middle Aged Neoplasm Staging - trends Oncology Precision Medicine - trends Preclinical Study Prognosis Survival United States |
| title | A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T18%3A37%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20retrospective%20prognostic%20evaluation%20analysis%20using%20the%208th%20edition%20of%20the%20American%20Joint%20Committee%20on%20Cancer%20staging%20system%20for%20breast%20cancer&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Lee,%20Sae%20Byul&rft.date=2018-06-01&rft.volume=169&rft.issue=2&rft.spage=257&rft.epage=266&rft.pages=257-266&rft.issn=0167-6806&rft.eissn=1573-7217&rft_id=info:doi/10.1007/s10549-018-4682-5&rft_dat=%3Cgale_pubme%3EA538168427%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1993603531&rft_id=info:pmid/29388016&rft_galeid=A538168427&rfr_iscdi=true |